^
Association details:
| Biomarker: | TP53 mutation + CARD11 mutation + SMARCA4 mutation |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Gazyva (obinutuzumab) (CD20 inhibitor) + Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3540 Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)
Published date:
11/04/2021
Excerpt:
One patient, who has TP53, CARD11, and SMARCA4 mutations, achieved stable disease at C3, converted to a partial response at C7, and is now progressing during C12….BOVen was well tolerated in untreated TP53 mutant MCL. The preliminary efficacy is promising in this high-risk subset of MCL.
Trial ID:
